Factors affecting outcome in hypoxic-ischemic encephalopathy in term infants.
Forty-nine term infants were prospectively shown to have hypoxic-ischemic encephalopathy (HIE). All infants survived the neonatal period, and all but two infants (seen at 12 months) were followed up to at least 27 months of age. Factors that significantly correlated with outcome included the Sarnat encephalopathy stage and the occurrence of intractable seizures not controlled by phenobarbital sodium alone. There was no association between the one- or five-minute Apgar score, the need for early ventilation, the EEG, the occurrence of seizures, and the subsequent outcome. There was no significant difference in outcome for those infants who received dexamethasone sodium phosphate (n = 29) v those who did not receive the drug (n = 20). A review of 97 term infants with HIE from a regional perinatal program during a one-year period (1979), including 35 of the 49 infants in the present study, did show a significant increase in morbidity and mortality for transported infants.
D000293:Adolescent; D000328:Adult; D002545:Brain Ischemia / Q000175:diagnosis*; D003907:Dexamethasone / Q000031:analogs & derivatives / Q000627:therapeutic use; D004569:Electroencephalography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D002534:Hypoxia, Brain / Q000175:diagnosis*; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008423:Maternal Age; D009460:Neurologic Examination; D010634:Phenobarbital / Q000627:therapeutic use; D011446:Prospective Studies; D014187:Transportation of Patients
C016356:dexamethasone sulfate ester; D003907:Dexamethasone; D010634:Phenobarbital